Erratum: Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women (Breast Cancer Res Treat DOI: 10.1007/s10549-009-0407-0);Genetic polymorphisms in phase i and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women

Breast Cancer Research and Treatment

Volumn 119, Issue 2, 2010, Pages 463-474

[No Author Info available]

Author keywords

Breast cancer risk; Gene environmental interaction; Hormone metabolism; Menopausal hormone therapy; Metabolizing enzymes

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; ESTROGEN; GESTAGEN; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 2B7; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE M3; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; GLYCOSYLTRANSFERASE; SULFOTRANSFERASE 1A1; TIBOLONE; TRANSFERASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ESTROGEN METABOLISM; ESTROGEN THERAPY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; MONOTHERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 74849096571     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0529-4     Document Type: Erratum

References (47)

1. V Beral 2003 Breast cancer and hormone-replacement therapy in the million women study Lancet 362 9382 419 427 10.1016/S0140-6736(03)14596-5 10.1016/S0140-6736(03)14065-2 1:CAS:528:DC%2BD3sXmt1ajsrw%3D 12927427
2. JE Rossouw GL Anderson RL Prentice AZ LaCroix C Kooperberg ML Stefanick RD Jackson SA Beresford BV Howard KC Johnson JM Kotchen J Ockene 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial JAMA 288 3 321 333 10.1001/jama.288.3.321 10.1001/jama.288.3.321 1:CAS:528: DC%2BD38Xltlegs7k%3D 12117397
3. D Flesch-Janys T Slanger E Mutschelknauss S Kropp N Obi E Vettorazzi W Braendle G Bastert S Hentschel J Berger J Chang-Claude 2008 Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy Int J Cancer 123 4 933 941 10.1002/ijc.23655 10.1002/ijc.23655 1:CAS:528:DC%2BD1cXovFWmu7o%3D 18506692 (Pubitemid 352032424)
4. PA Newcomb L Titus-Ernstoff KM Egan A Trentham-Dietz JA Baron BE Storer WC Willett MJ Stampfer 2002 Postmenopausal estrogen and progestin use in relation to breast cancer risk Cancer Epidemiol Biomarkers Prev 11 7 593 600 1:CAS:528:DC%2BD38Xmt1Wks7g%3D 12101105 (Pubitemid 34760816)
5. RK Ross A Paganini-Hill PC Wan MC Pike 2000 Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin J Natl Cancer Inst 92 4 328 332 10.1093/jnci/92.4.328 10.1093/jnci/92.4.328 1:CAS:528:DC%2BD3cXhsVGqtrs%3D 10675382
6. C Schairer J Lubin R Troisi S Sturgeon L Brinton R Hoover 2000 Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk JAMA 283 4 485 491 10.1001/jama.283.4.485 10.1001/jama.283.4.485 1:CAS:528:DC%2BD3cXns1GltA%3D%3D 10659874 (Pubitemid 30062864)
7. H Seeger AO Mueck 2008 Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data J Steroid Biochem Mol Biol 109 1-2 11 15 10.1016/j.jsbmb.2007.12.002 10.1016/j.jsbmb.2007.12.002 1:CAS:528:DC%2BD1cXjtlemtrk%3D 18206365
8. B Zumoff 1998 Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy Proc Soc Exp Biol Med 217 1 30 37 1:CAS:528:DyaK1cXlsFSn 9421204
9. M Poutanen V Isomaa H Peltoketo R Vihko 1995 Role of 17 beta-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis J Steroid Biochem Mol Biol 55 5-6 525 532 10.1016/0960-0760(95) 00201-4 10.1016/0960-0760(95)00201-4 1:CAS:528:DyaK28Xkt1Sjtw%3D%3D 8547177 (Pubitemid 26019338)
10. KJ Pawlak JP Wiebe 2007 Regulation of estrogen receptor (ER) levels in MCF-7 cells by progesterone metabolites J Steroid Biochem Mol Biol 107 3-5 172 179 10.1016/j.jsbmb.2007.05.030 10.1016/j.jsbmb.2007.05.030 1:CAS:528: DC%2BD2sXhtVCisbzF 17683929 (Pubitemid 47380373)
11. JP Wiebe 2006 Progesterone metabolites in breast cancer Endocr Relat Cancer 13 3 717 738 10.1677/erc.1.01010 10.1677/erc.1.01010 1:CAS:528: DC%2BD28XhtlequrzM 16954427 (Pubitemid 44763254)
12. JP Wiebe L Souter G Zhang 2006 Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment J Steroid Biochem Mol Biol 100 4-5 129 140 10.1016/j.jsbmb.2006.03.010 10.1016/j.jsbmb.2006.03.010 1:CAS:528:DC%2BD28XotFWlsrY%3D 16806904 (Pubitemid 44175837)
13. FP Guengerich 2001 Forging the links between metabolism and carcinogenesis Mutat Res 488 3 195 209 10.1016/S1383-5742(01)00059-X 10.1016/S1383-5742(01)00059-X 1:CAS:528:DC%2BD3MXktVOgsLg%3D 11397649 (Pubitemid 32521032)
14. CA Smith G Smith CR Wolf 1994 Genetic polymorphisms in xenobiotic metabolism Eur J Cancer 30A 13 1921 1935 10.1016/0959-8049(94)00382-F 10.1016/0959-8049(94)00382-F 1:CAS:528:DyaK2MXkt1eksLc%3D 7734203 (Pubitemid 24382590)
15. RJ Turesky 2004 The role of genetic polymorphisms in metabolism of carcinogenic heterocyclic aromatic amines Curr Drug Metab 5 2 169 180 10.2174/1389200043489036 10.2174/1389200043489036 1:CAS:528:DC%2BD2cXjt1Oku7s%3D 15078194 (Pubitemid 38519058)
16. KF Windmill RA McKinnon X Zhu A Gaedigk DM Grant ME McManus 1997 The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies Mutat Res 376 1-2 153 160 10.1016/S0027-5107(97)00038-9 1:CAS:528:DyaK2sXislemtb8%3D 9202751 (Pubitemid 27248598)
17. U Brockstedt M Krajinovic C Richer G Mathonnet D Sinnett W Pfau D Labuda 2002 Analyses of bulky DNA adduct levels in human breast tissue and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1), and glutathione S-transferases (GSTs) Mutat Res 516 1-2 41 47 1:CAS:528:DC%2BD38Xis1entLg%3D 11943609
18. R Kaaks S Rinaldi TJ Key F Berrino PH Peeters C Biessy L Dossus A Lukanova S Bingham KT Khaw NE Allen HB Bueno-de-Mesquita CH van Gils D Grobbee H Boeing PH Lahmann G Nagel J Chang-Claude F Clavel-Chapelon A Fournier A Thiebaut CA Gonzalez JR Quiros MJ Tormo E Ardanaz P Amiano V Krogh D Palli S Panico R Tumino P Vineis A Trichopoulou V Kalapothaki D Trichopoulos P Ferrari T Norat R Saracci E Riboli 2005 Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition Endocr Relat Cancer 12 4 1071 1082 10.1677/erc.1.01038 10.1677/erc.1.01038 1:CAS:528:DC%2BD28XnvVyhsA%3D%3D 16322344 (Pubitemid 41815798)
19. T Key P Appleby I Barnes G Reeves 2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies J Natl Cancer Inst 94 8 606 616 1:CAS:528:DC%2BD38Xjs1eit7w%3D 11959894
20. EL Cavalieri EG Rogan 2004 A unifying mechanism in the initiation of cancer and other diseases by catechol quinones Ann N Y Acad Sci 1028 247 257 10.1196/annals.1322.029 10.1196/annals.1322.029 1:CAS:528:DC%2BD2MXivFWgu7g%3D 15650250 (Pubitemid 40361826)
21. B Pesch Y Ko H Brauch U Hamann V Harth S Rabstein C Pierl HP Fischer C Baisch C Justenhoven U Ranft T Bruning 2005 Factors modifying the association between hormone-replacement therapy and breast cancer risk Eur J Epidemiol 20 8 699 711 10.1007/s10654-005-0032-0 10.1007/s10654-005-0032-0 16151884 (Pubitemid 41266867)
22. IE Andonova RB Sarueva AD Horvath VA Simeonov PS Dimitrov EA Petropoulos VS Ganev 2004 Balkan endemic nephropathy and genetic variants of glutathione S-transferases J Nephrol 17 3 390 398 1:CAS:528:DC%2BD2cXnsFOqu70%3D 15365959
23. C Kohle B Mohrle PA Munzel M Schwab D Wernet OA Badary KW Bock 2003 Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP- glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians Biochem Pharmacol 65 9 1521 1527 10.1016/S0006-2952(03) 00074-1 10.1016/S0006-2952(03)00074-1 1:CAS:528:DC%2BD3sXjsVeqtr4%3D 12732365 (Pubitemid 36555839)
24. SL Lake H Lyon K Tantisira EK Silverman ST Weiss NM Laird DJ Schaid 2003 Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous Hum Hered 55 1 56 65 10.1159/000071811 10.1159/000071811 1:STN:280:DC%2BD3szlvVWjug%3D%3D 12890927 (Pubitemid 36928747)
25. M Obreiter C Fischer J Chang-Claude L Beckmann 2005 SDMinP: a program to control the family wise error rate using step-down minP adjusted P-values Bioinformatics 21 14 3183 3184 10.1093/bioinformatics/bti480 10.1093/bioinformatics/bti480 1:CAS:528:DC%2BD2MXlslykt74%3D 15879457 (Pubitemid 41418478)
26. Westfall PH, Young SS (1993) Resampling-based multiple testing: examples and methods for P-value adjustment. John Wiley & Sons, Inc., New York
27. R Development Core Team (2005) R: a language and environment for statistical computing. R foundation for statistical computing, Ref type: computer program, Vienna, Austria
28. CM McBride LC Brody 2007 Point: genetic risk feedback for common disease time to test the waters Cancer Epidemiol Biomarkers Prev 16 9 1724 1726 10.1158/1055-9965.EPI-07-0102 10.1158/1055-9965.EPI-07-0102 17855688 (Pubitemid 47450500)
29. PA Thompson 2007 Counterpoint: genetic risk feedback for common disease time to test the waters Cancer Epidemiol Biomarkers Prev 16 9 1727 1729 10.1158/1055-9965.EPI-07-0213 10.1158/1055-9965.EPI-07-0213 17855689
30. TC Cheng ST Chen CS Huang YP Fu JC Yu CW Cheng PE Wu CY Shen 2005 Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility Int J Cancer 113 3 345 353 10.1002/ijc.20630 10.1002/ijc.20630 1:CAS:528: DC%2BD2MXhsFSl 15455371 (Pubitemid 40038699)
31. R Raftogianis C Creveling R Weinshilboum J Weisz 2000 Estrogen metabolism by conjugation J Natl Cancer Inst Monogr 27 113 124 1:CAS:528: DC%2BD3cXlvVSntbo%3D 10963623
32. R Sparks CM Ulrich J Bigler SS Tworoger Y Yasui KB Rajan P Porter FZ Stanczyk R Ballard-Barbash X Yuan MG Lin L McVarish EJ Aiello A McTiernan 2004 UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients Breast Cancer Res 6 5 R488 R498 10.1186/bcr818 10.1186/bcr818 1:CAS:528: DC%2BD2cXmtVegt7k%3D 15318931
33. SK Srivastava SS Singhal X Hu YC Awasthi P Zimniak SV Singh 1999 Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa Arch Biochem Biophys 366 1 89 94 10.1006/abbi.1999.1217 10.1006/abbi.1999.1217 1:CAS:528:DyaK1MXjtFKhsLg%3D 10334868 (Pubitemid 29394233)
34. K Mitrunen N Jourenkova V Kataja M Eskelinen VM Kosma S Benhamou H Vainio M Uusitupa A Hirvonen 2001 Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer Cancer Epidemiol Biomarkers Prev 10 3 229 236 1:CAS:528:DC%2BD3MXjtVWmsbo%3D 11303592
35. T Rylander-Rudqvist S Wedren F Granath K Humphreys S Ahlberg E Weiderpass M Oscarson M Ingelman-Sundberg I Persson 2003 Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk Carcinogenesis 24 9 1533 1539 10.1093/carcin/bgg114 10.1093/carcin/bgg114 1:CAS:528:DC%2BD3sXnt1Kjs7s%3D 12844487 (Pubitemid 37160844)
36. TR Rebbeck AB Troxel EG Shatalova R Blanchard S Norman G Bunin A DeMichele R Schinnar JA Berlin BL Strom 2007 Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk Cancer Epidemiol Biomarkers Prev 16 6 1318 1320 10.1158/1055-9965.EPI-07-0084 10.1158/1055-9965.EPI-07-0084 1:CAS:528:DC%2BD2sXmtVKnur4%3D 17548708 (Pubitemid 46984981)
37. B Diergaarde JD Potter ER Jupe S Manjeshwar CD Shimasaki TW Pugh DC Defreese BA Gramling I Evans E White 2008 Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer Cancer Epidemiol Biomarkers Prev 17 7 1751 1759 10.1158/1055-9965.EPI-08-0168 10.1158/1055-9965.EPI-08-0168 1:CAS:528: DC%2BD1cXosFGhtr4%3D 18628428
38. CL Hayes DC Spink BC Spink JQ Cao NJ Walker TR Sutter 1996 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1 Proc Natl Acad Sci U S A 93 18 9776 9781 10.1073/pnas.93.18.9776 10.1073/pnas.93.18.9776 1:CAS:528:DyaK28XlsFehsbc%3D 8790407 (Pubitemid 26296685)
39. AJ Lee MX Cai PE Thomas AH Conney BT Zhu 2003 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms Endocrinology 144 8 3382 3398 10.1210/en.2003-0192 10.1210/en.2003-0192 1:CAS:528:DC%2BD3sXlslGjsb0%3D 12865317 (Pubitemid 36904414)
40. IH Hanna S Dawling N Roodi FP Guengerich FF Parl 2000 Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity Cancer Res 60 13 3440 3444 1:CAS:528:DC%2BD3cXkvFChs7s%3D 10910054
41. J Watanabe T Shimada EM Gillam T Ikuta K Suemasu Y Higashi O Gotoh K Kawajiri 2000 Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer Pharmacogenetics 10 1 25 33 10.1097/00008571-200002000- 00004 10.1097/00008571-200002000-00004 1:CAS:528:DC%2BD3cXhvFGitLc%3D 10739169 (Pubitemid 30142810)
42. SV Fernandez IH Russo J Russo 2006 Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells Int J Cancer 118 8 1862 1868 10.1002/ijc.21590 10.1002/ijc.21590 1:CAS:528:DC%2BD28Xjt1GqtLk%3D 16287077
43. Z Zhao W Kosinska M Khmelnitsky EL Cavalieri EG Rogan D Chakravarti PG Sacks JB Guttenplan 2006 Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol Chem Res Toxicol 19 3 475 479 10.1021/tx0502645 10.1021/tx0502645 1:CAS:528:DC%2BD28XhtVKjtb0%3D 16544955
44. Z Wawrzak WL Duax PD Strong J Weisz 1998 Steroid structure and function. Molecular conformation of 4-hydroxyestradiol and its relation to other catechol estrogens J Steroid Biochem 29 4 387 392 10.1016/0022-4731(88)90247-6 10.1016/0022-4731(88)90247-6
45. T Shimada J Watanabe K Kawajiri TR Sutter FP Guengerich EM Gillam K Inoue 1999 Catalytic properties of polymorphic human cytochrome P450 1B1 variants Carcinogenesis 20 8 1607 1613 10.1093/carcin/20.8.1607 10.1093/carcin/20.8.1607 1:CAS:528:DyaK1MXltlKnsrg%3D 10426814 (Pubitemid 29385452)
46. AF Badawi EL Cavalieri EG Rogan 2001 Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol Metabolism 50 9 1001 1003 10.1053/meta.2001.25592 10.1053/meta.2001.25592 1:CAS:528:DC%2BD3MXmvFWgurY%3D 11555828 (Pubitemid 32904154)
47. AE Cribb MJ Knight D Dryer J Guernsey K Hender M Tesch TM Saleh 2006 Role of polymorphic human cytochrome P450 enzymes in estrone oxidation Cancer Epidemiol Biomarkers Prev 15 3 551 558 10.1158/1055-9965.EPI-05-0801 10.1158/1055-9965.EPI-05-0801 1:CAS:528:DC%2BD28Xit1OmsL0%3D 16537715